[1]柳小远 于小勇.2020年版中成药治疗慢性肾脏病3-5期 (非透析)临床应用指南解读[J].现代中医药,2021,(05):014-18.[doi:10.13424/j.cnki.mtcm.2021.05.003]
 LIU Xiaoyuan YU Xiaoyong.Interpretation of 2020 Version of The Clinical Application Guide of Chinese Patent Medicine in The Treatment of Chronic Kidney Disease Stage 3-5 (Non Dialysis)[J].Modern Traditional Chinese Medicine,2021,(05):014-18.[doi:10.13424/j.cnki.mtcm.2021.05.003]
点击复制

2020年版中成药治疗慢性肾脏病3-5期 (非透析)临床应用指南解读
分享到:

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2021年05期
页码:
014-18
栏目:
指南与共识
出版日期:
2021-09-23

文章信息/Info

Title:
Interpretation of 2020 Version of The Clinical Application Guide of Chinese Patent Medicine in The Treatment of Chronic Kidney Disease Stage 3-5 (Non Dialysis)
文章编号:
1672-0571(2021)05-0014-05
作者:
柳小远 于小勇
陕西省中医医院,陕西 西安 710000
Author(s):
LIU Xiaoyuan YU Xiaoyong
Shaanxi Traditional Chinese Medicine Hospital,Xian 710000,China
关键词:
中成药慢性肾衰竭临床实践指南解读
Keywords:
Chinese patent medicineChronic renal failureClinical practice guidelinesInterpretion
分类号:
R256.5
DOI:
10.13424/j.cnki.mtcm.2021.05.003
文献标志码:
A
摘要:
2020年《中成药治疗优势病种临床应用指南》标准化项目组正式发布了《中成药治疗慢性肾脏病3-5期(非透析)临床应用指南》。该指南基于解决临床关键问题,涵盖了临床常用的治疗慢性肾脏病的中成药的临床指标改善情况、使用条件、安全性及证据描述,共计8条推荐意见。结合指南,主要介绍该指南的制订背景和方法学,并对临床常用的治疗慢性肾脏病3-5期(非透析)的主要中成药的相关内容进行解读。
Abstract:
In 2020,the standardization project team of the Clinical Application Guide of Chinese Patent Medicine in The Treatment of Dominant Diseases officially released the Clinical Application Guide of Chinese Patent Medicine in The Treatment of Chronic Kidney Disease Phase 3-5 (Non Dialysis).Based on solving key clinical problems,the guide covers the improvement of clinical indicators,use conditions,safety and evidence description of Chinese patent medicines commonly used in clinical treatment of chronic kidney disease,with a total of 8 recommendations.This paper introduces the background and methodology of the guideline,and interprets the relevant contents of the main Chinese patent medicines commonly used in the clinical treatment of stage 3-5 (non dialysis) of chronic kidney disease.

参考文献/References:

[1]雷蕾,熊维建,钟锦,等.《慢性肾衰竭中医诊疗指南》临床应用评价体会\[J\].中华中医药杂志,2016,31(9):3617-3619.
[2]Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey\[J\].The Lancet,2012,379(9818):815-822.
[3]陈香美,王海燕.提高慢性肾脏病的知晓率、治疗率和控制率减轻对国民健康的危害\[J\].中华内科杂志,2006,45(6):441-442.
[4]刘开翔,田冬琴,冯杰,等.慢性肾脏病高尿酸血症危害及管理研究进展\[J\].西部医学,2019,31(2):322-325.
[5]Stevens Paul E,Levin Adeera.Evaluation and management of chronic kidney disease:synopsis of the kidney disease:improving global outcomes 2012 clinical practice guideline\[J\].Annals of internal medicine,2013,158(11).
[6]陈云,傅文宁,鲁盈.中医药对慢性肾脏病5期(非透析)患者治疗优势的临床研究\[J\].世界中医药,2018,13(6):1337-1341.
[7]《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗慢性肾脏病3~5期(非透析)临床应用指南(2020年)\[J\].中国中西医结合杂志,2021,41(3):261-272.
[8]俞辉,彭文,王云满.中医药治疗慢性肾脏病疗效优势\[J\].吉林中医药,2014,34(6):637-639.
[9]Schunemann HJ,Best D,Vist G,et al.Letters,numbers,symbols and words:how to communicate grades of evidence and recommendations\[J\].CMAJ,2003,169(7):77-680.
[10]Andrews J,Guyatt G,Oxman AD,et al.GRADE guidelines:14.Going from evidence to recommendations:the significance and presentation of recommendations\[J\].Journal of Clinical Epidemiology,2013,66(7):719-725.
[11]韩宇鹏,孟庆云,杨舒贺,等.尿毒清颗粒对单侧输尿管梗阻大鼠肾间质纤维化及肾功能和转化生长因子-β1表达的影响\[J\].中国老年学杂志,2020,40(22):4839-4841.
[12]翁育才,王高岸,王炜,等.托伐普坦联合尿毒清颗粒治疗肾病综合征患者的临床研究\[J\].中华全科医学,2020,18(10):1638-1640,1773.
[13]蓝雅琳,杜笠,蒋成燕,等.尿毒清颗粒联合氯沙坦钾治疗早期糖尿病肾病的疗效及对氧化应激指标的影响\[J\].中华中医药学刊,2021,39(4):56-59.
[14]孙顺辉,李波.肾衰宁胶囊治疗慢性肾衰竭早中期患者的疗效及对肾功能指标的影响\[J\].世界中医药,2017,12(6):1306-1309.
[15]李永伟,李慧,陈婧,等.肾衰宁胶囊联合包醛氧淀粉治疗慢性肾功能衰竭患者的临床研究\[J\].中国临床药理学杂志,2020,36(21):3429-3432.
[16]陈香美,李平,孙雪峰,等.肾康制剂(肾康注射液、肾康栓)治疗慢性肾脏病合理应用专家共识\[J\].中国中西医结合杂志,2019,39(7):784-786.
[17]王存良,施亚敏,付智慧,等.基于网络药理学的肾康注射液治疗慢性肾功能衰竭作用机制研究\[J\].现代药物与临床,2021,36(1):1-8.
[18]莫嘉浩,綦向军,许洪彬,等.中药注射液治疗慢性肾功能不全的贝叶斯网状Meta分析\[J\].中国中药杂志,2021,46(2):454-466.
[19]刘枚芳,黄家晟,何嘉炜,等.海昆肾喜胶囊治疗慢性肾功能衰竭的Meta分析\[J\].中国药房,2017,28(27):3801-3804.
[20]黎雾峰,王晶,王毅,等.参芪地黄汤联合海昆肾喜胶囊辅助治疗对慢性肾衰竭患者肾功能及氧化应激的影响\[J\].现代中西医结合杂志,2020,29(29):3222-3225,3235.
[21]龚丽,黄寅銮,谢韶妍,等.百令胶囊联合缬沙坦治疗糖尿病肾病临床疗效及安全性的Meta分析\[J\].广州中医药大学学报,2021,38(5):1061-1066.
[22]Hu Xiuhong,Wang Jing,Yang Hongjuan,et al.Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease:Protocol of a double-blinded,randomized,controlled trial\[J\].Medicine,2021,100(20).
[23]连心逸,柳红芳,王向明,等.金水宝胶囊联合血管紧张素转换酶抑制剂治疗糖尿病肾病系统评价\[J\].中国中医药信息杂志,2020,27(9):103-107.
[24]杜卉莲.黄葵胶囊联合缬沙坦和雷公藤多苷片治疗慢性肾炎的疗效及对患者血脂代谢及肾功能的影响\[J\].检验医学与临床,2019,16(21):3158-3160.
[25]滕雅芹,徐鑫淼,郑丽红,等.西格列汀片联合黄葵胶囊治疗早期糖尿病肾病的效果观察及对CysC、Hcy、mALB的影响\[J/OL\].中华中医药学刊:1-9\[2021-05-28\].
[26]谷粒,胡耀,彭璇,等.肾炎康复片结合氯沙坦钾片治疗慢性肾小球肾炎临床疗效及对IL-1β、IL-1及VEGF水平的影响\[J\].中华中医药学刊,2021,39(5):213-216.
[27]Wu Jie,Duan Shu-wei,Yang Hong-tao,et al.Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial\[J\].Journal of Integrative Medicine,2021,19(2):111-119.
[28]王晶,柴立超,刘爱翔,等.肾炎康复片联合舒洛地特治疗肾病综合征合并类固醇糖尿病疗效及对β2-MG、CRP、HCY水平的影响\[J\].中华中医药学刊,2021,39(4):232-236.
[29]汤晓静,戎殳,梅长林,倪兆慧,等.生血宁片对非透析慢性肾脏病肾性贫血患者的临床疗效\[J\].中成药,2019,41(2):316-321.
[30]刘雪莉,陈凯,史红,等.铁叶绿酸钠对正常小鼠祖细胞集落和实验性贫血的影响\[J\].中华血液学杂志,1997,18(5):11-13.

相似文献/References:

[1]张茹?杜娟.五指毛桃的研究进展[J].现代中医药,2021,(05):048.[doi:10.13424/j.cnki.mtcm.2021.05.008]
[2]柳小远,于小勇.中成药治疗糖尿病肾脏病临床应用专家共识指南解读[J].现代中医药,2023,(01):024.[doi:10.13424/j.cnki.mtcm.2023.01.005]
 Liu Xiaoyuan?YU Xiaoyong.Interpretation of Expert Consensus Guidelines for Clinical Application of Chinese Patent Medicine in Treatment of Diabetes Kidney Disease[J].Modern Traditional Chinese Medicine,2023,(05):024.[doi:10.13424/j.cnki.mtcm.2023.01.005]
[3]袁普卫 刘德玉 李堪印.强化循证实践,重视中成药规范应用 ——《中成药治疗膝骨关节炎临床应用指南》(2020年)解读*[J].现代中医药,2023,(02):023.[doi:10.13424/j.cnki.mtcm.2023.02.005 ]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局科研项目(2021-GJ-LC022)
更新日期/Last Update: 2021-09-24